glp-1 obesity drug news today september 29 2025 FDA takes aim at telehealth companies for promoting unofficial weight loss dupes GLP-1 Weight-Loss Drug Demonstration Begins

Multi-indication label expansion: Semaglutide approved across obesity, cardiovascular risk reduction, MASH, and sleep apnea creates a total addressable patient population of approximately 640 million globally nearly four times the obesity-only base adding new prescriber populations including cardiologists, hepatologists, and sleep medicine specialists

Some protocols use BPC-157 only during the GLP-1 titration phase when GI support is most needed, then discontinue it once the maintenance dose is reached and well-tolerated

Cold Plasma Plus+ The Intensive Hydrating Complex (30 mL / 1 US fl

Collection Oral Pathology Review Images Contributors Page, Dennis

Tried minoxidil for about eight months and saw some results, but the twice-daily application got old fast

New York: Springer-Verlag